Draft End of Enrolment Message

First Page		Document Content
Date: 2008-08-20 15:26:20 Health Microbicides Development Programme Vaginal microbicide PRO HIV Microbicides for sexually transmitted diseases Clinical trial CAPRISA 004 Microbicides Microbiology Medicine		Draft End of Enrolment Message Add to Reading List Source URL: www.mdp.mrc.ac.uk Download Document from Source Website File Size: 30,56 KB Share Document on Facebook

	Press Release: MayOmololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Presented to a Pioneering Community Educator Who Brings the Voices of Community Members and Participants t DocID: 1gbaX - View Document
	FACTS 001 QA 2.9.14_MB MS LC KA.docx.docx DocID: 1fD6y - View Document
	Using Antiretrovirals to Prevent HIV: Implications of the outcome of the CAPRISA 004 tenofovir-gel microbicide trial SAVE THE DATE: Tuesday, 20 July 2010, 6.30pm-8.30pm An official satellite of XVII International AIDS Co DocID: 1deAN - View Document
	Results of the CAPRISA 004 trial of tenofovir gel Salim S Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director: CAPRISA DocID: 1ci9M - View Document
	What is CAPRISA 004? CAPRISA 004 was a phase IIb, two-arm, double-blind, randomised, placebo-controlled trial designed to assess the safety and effectiveness of the vaginal microbicide candidate 1% tenofovir gel for the DocID: 1bY73 - View Document